If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
236
results.
Updated on
14/07/2025 [06:52:00]
Results 200 to 225 of 236
Absstract of: AU2023379598A1
Novel ionizable lipids are provided. Also provided are novel lipid nanoparticle compositions for the delivery of nucleic acid material to cells in vitro and in vivo with different and improved pharmacokinetic profiles as compared to what is typically observed in the art. Also provided are methods for using the compositions in research and as therapeutics.
Absstract of: CN120227459A
本发明公开了一种诱发细胞焦亡的纳米转换器及其制备方法与应用。所述纳米转换器的制备原料包括能量供体、光敏剂、胆固醇氧化酶和马来酰亚胺‑1，2‑二硬脂酰基‑sn‑甘油‑3‑磷酸乙醇胺‑聚(乙二醇)(Mal‑DSPE‑PEG)。所述纳米转换器中双草酸酯与二氢卟吩e6通过亲疏水相互作用与Mal‑DSPE‑PEG形成纳米胶束，胆固醇氧化酶通过和马来酰亚胺反应而被修饰在纳米胶束的表面。所述纳米转换器可以有效的将肿瘤衰老细胞中的胆固醇和过氧化氢转换为单线态氧最终导致肿瘤衰老细胞的焦亡。本发明公开的纳米转换器由于靶向了肿瘤衰老细胞普遍存在的代谢特征而具有普适性和高的安全性。此外该纳米转换器利用化学能驱动光动力学治疗，由于不依赖外在光源而降低了可能存在的光毒性。
Absstract of: CN120230169A
本发明提供了一种具有式(I)所示结构的可电离阳离子脂质化合物，其可用于制备用于递送治疗剂和/或预防剂的脂质纳米颗粒(LNP)。利用本发明的可电离阳离子脂质化合物制备的LNP具有较佳的稳定性和转染效率，可以高效地、稳定地将生物活性物质(包括核酸，例如mRNA)递送至靶细胞或器官，从而在体内引起高特异性抗体应答。#imgabs0#
Absstract of: CN120227356A
本发明公开了一种载亚硝基血红蛋白的膜融合仿生纳米载体、其制备方法和应用；所述膜融合仿生纳米载体，其膜壳由合成磷脂与血小板膜杂化融合而成，膜壳内包封有亚硝基血红蛋白的水溶液，所述亚硝基血红蛋白是由血红蛋白经脱氧处理后，与一氧化氮分子反应制备而成；所述膜融合仿生纳米载体具有良好的生物相容性和天然靶向性，可以快速、高效地靶向心脑血管疾病病灶，所递送的亚硝基血红蛋白不仅保留了一氧化氮气体分子的血管扩张等生物活性，同时具有顺磁性，可有效增强磁共振显影效果，可作为载体为一氧化氮分子在缺血性心脑血管疾病病灶的有效递送和磁共振影像诊断提供了新工具。
Absstract of: CN120227355A
本发明公开了一种骨髓基质细胞膜仿生载药CX4945纳米递送系统及其制备方法和应用。骨髓基质细胞膜仿生载药CX4945纳米递送系统以被高分子聚合物包被的CX4945药物为内核，基质细胞膜为壳层，其可以使CX4945缓慢释放，延长了药物的半衰期，降低了CX4945的用药频率；可以通过基质细胞膜上的CXCL12与B‑ALL细胞表面过表达的CXCR4特异性结合，提高了B‑ALL细胞对于CX4945药物的摄取，增强药物对肿瘤细胞的杀伤，实现CX4945药物的精准递送；还可以通过阻断CXCR4/CXCL12生物轴，阻止B‑ALL细胞归巢，解决其转移、复发、耐药等问题。
Absstract of: CN120227363A
本发明涉及一种基于白藜芦醇制备纳米金复合物治疗肺癌的方法，本发明涉及一种用于治疗肺癌的创新药物复合物，其核心组成为白藜芦醇修饰的纳米金。在肺癌治疗领域，传统疗法的局限性促使我们寻求新的治疗途径。白藜芦醇是一种天然的多酚化合物，具有抗氧化、抗炎和抗癌特性。纳米金作为药物递送的理想载体，具有良好的生物相容性和可调控的表面性质。因此，将白藜芦醇修饰到纳米金表面，形成药物复合物，有望克服传统治疗的限制，提供更为安全和有效的治疗选择。在本发明中，我们首先通过适当的化学合成方法制备了白藜芦醇修饰的纳米金。这一步骤涉及表面修饰和功能化，以确保纳米金的稳定性和药物修饰的成功。接着，我们通过适当的途径，例如药物递送系统或载体，将该药物复合物引导至肺癌细胞，以提高靶向性和治疗效果。实验结果表明，本发明的药物复合物在肺癌细胞中展现出显著的抗增殖和诱导凋亡效果。动物实验结果进一步验证了该药物复合物在体内的疗效和安全性。这些数据支持了本发明在肺癌治疗中的创新性和实用性。
Absstract of: CN120227373A
本发明涉及一种基于青蒿素制备纳米金复合物治疗腹膜癌的方法，旨在制备并修饰纳米金颗粒，以用于腹膜癌的治疗。该复合物由青蒿素修饰的纳米金组成。该复合物以其卓越的生物相容性和高度的靶向性，为腹膜癌治疗领域带来了全新的治疗方案。通过将青蒿素修饰的纳米金引导至腹膜癌细胞，本发明旨在提高治疗的精确性和效果，从而降低治疗过程中对正常细胞的损伤。
Absstract of: CN120227354A
本发明提供了一种用于核酸药物递送的脂质纳米颗粒组合物及其制备方法和应用。本发明提供的脂质纳米颗粒组合物包含类固醇‑阳离子脂质化合物、中性磷脂、和聚乙二醇脂质三种脂质成分。混合制备的组合物具有较佳的稳定性和转染效率。利用将脂质纳米颗粒用于递送核酸，例如mRNA，可以高效稳定的将核酸药物递送至靶细胞或器官，在实验动物体内可引起较高的特异性抗体应答，且化合物具有更好的安全性。
Absstract of: AU2023382536A1
The present invention refers to novel polyoxyalkylene based compounds and their manufacturing method as well as compositions comprising at least one novel polyoxyalkylene based compound and at least one active agent. Furthermore, the present invention refers to the manufacture of the compositions of the present invention as well as their use for the treatment of an illness in mammals or humans.
Absstract of: AU2023331445A1
The present application relates to indazole derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptors in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptors in a cell. The diseases, disorders or conditions include, for example, psychosis, mental illnesses and CNS disorders. Formula (I) wherein Q is selected from (Q1), (Q2), (Q3), (Q4) (Q5) and (Q6)
Absstract of: CN120227357A
本发明提供一种细胞膜囊泡包裹的碳酸镁锰纳米颗粒及其制备方法与应用，所述纳米颗粒包含：高表达PD1的肿瘤细胞来源膜囊泡；以及包裹于囊泡内的MgMn纳米颗粒复合物；本发明提供的细胞膜囊泡包裹的碳酸镁锰纳米颗粒(CVs@MgMn)集Mg2+、Mn2+离子的众多优点于一身，除了复合纳米颗粒本身具有调控免疫和肿瘤杀伤效果之外，还能实现放疗增敏，且对任意类型实体瘤具有免疫调控和微环境重塑作用，是一款通用型的多功能复合纳米颗粒。
Absstract of: CN120227445A
本发明公开了一种透皮利拉鲁肽纳米粒及其制备方法和应用，所述利拉鲁肽纳米粒为核壳结构，其中核心包括利拉鲁肽与酚羟基多酚化合物的络合物，核壳为季铵化壳聚糖。酚羟基多酚化合物的多个酚羟基团可作为氢键作用位点与利拉鲁肽结合形成纳米颗粒，填补了利拉鲁肽纳米粒的技术空白，该发明也适用于其它多肽类分子纳米颗粒的制备。纳米颗粒再与正电性季铵化壳聚糖(HTCC)结合形成核壳结构的利拉鲁肽纳米粒。HTCC通过改变角质蛋白的二级结构来促进药物渗透皮肤，并且其表面带有的高浓度正电荷，可与皮肤角质层的负电荷磷脂双分子层形成强静电吸附，相比于壳聚糖具有更强的皮肤渗透能力，有助于应用于透皮给药制剂中。
Absstract of: EP4382127A2
The present disclosure is directed to antibodies binding to Glypican 2 and methods of using such antibodies to treat cancers that express or overexpress the Glypican 2 antigen.
Absstract of: US2025114475A1
A fusion protein comprises a nanocage monomer; and an antibody or fragment thereof linked to the nanocage monomer, the antibody or fragment thereof comprising a first member of a binding pair; wherein a plurality of the fusion proteins self-assemble to form a nanocage in which a plurality of the antibodies or fragments thereof decorate the exterior surface of the nanocage, whereby the first member of the binding pair is exposed for interacting with a second member of a binding pair.
Absstract of: US2022409540A1
The present invention provides a vaccine for preventing and/or treating infections with human papillomavirus. The present invention relates to a lipid particle encapsulating a nucleic acid molecule capable of expressing the E6 and E7 antigens of human papillomavirus, wherein the lipid comprises a cationic lipid represented by general formula (Ia) or a pharmaceutically acceptable salt thereof:wherein R1 and R2 each independently represent a C1-C3 alkyl group;L1 represents a C17-C19 alkenyl group which may have one or a plurality of C2-C4 alkanoyloxy groups;L2 represents a C10-C19 alkyl group which may have one or a plurality of C2-C4 alkanoyloxy groups or a C10-C19 alkenyl group which may have one or a plurality of C2-C4 alkanoyloxy groups; andp is 3 or 4.
Absstract of: US2025152587A1
A compound of formula Ior a pharmaceutically acceptable salt or ester thereof is provided for the treatment of cancer wherein(i) the cancer is one that has the characteristic of being a type prone to being or becoming refractory or resistant to platinum drug based therapy and(ii) the treatment is with a dose of between 1 mg/m2 and 30 mg/m2 of compound per patient body surface area per administration.Method of treatment and novel dosage forms are also provided.Particularly treated are ovarian cancers, particularly those expressing α-folate receptors, including epithelial ovarian, fallopian tube or peritoneal cancer.
Absstract of: US2025152563A1
The present invention provides methods and compositions for treating a hyperplasia (such as cancer, restenosis, or pulmonary hypertension) by administering a composition comprising nanoparticles that comprise an mTOR inhibitor (such as a limus drug) and an albumin based upon the status of an mTOR-activating aberration.
Absstract of: MX2024013597A
The invention provides lipid nanoparticle-based compositions with improved properties for delivery of biologically active agents, engineered cells, and methods for delivery of the agents.
Absstract of: AU2023406303A1
Provided herein are lipid nanoparticle (LNP) compositions (e.g., pharmaceutical compositions) comprising a therapeutic nucleic acid (TNA), wherein the LNP comprises an ionizable lipid; a "helper" lipid, e.g., a ceramide or distearoylphosphatidylcholine (DSPC); a structural lipid, e.g., a sterol; and one or more types of lipid-anchored polymers, as well as uses thereof.
Absstract of: AU2023406947A1
The present application discloses modified single-stranded DNA molecules, as well as their cell-free methods of synthesis and their use as therapeutic agents.
Absstract of: AU2023406321A1
The present disclosure provides novel polymer-conjugated lipids, e.g., comprising DODA conjugated to a polyglycerol or a polyglycerol derivative. The present disclosure also provides lipid nanoparticles (LNPs) formulation using the polymer-conjugated lipids and methods of treating a disease by administering the LNP formulations.
Absstract of: US2025099477A1
The present invention provides prodrugs and methods of use thereof.
Absstract of: AU2023406483A1
The present disclosure provides stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types,
Absstract of: WO2024110835A1
There are disclosed uses of compositions for the preparation of medications for the treatment of a subject or an object in need thereof, the compositions comprising nano-elements containing: a) at least one water-insoluble thermoplastic compound (WITC), capable of forming a core; and b) at least one active agent which can be disposed in said core or in shells surrounding the core. The nano-elements, having an average diameter in the sub-micron range, are constituted of materials having a low vapor pressure and are dispersible in a polar carrier. Methods for preparing these nano-elements, and administering them, so as to treat conditions corresponding to the active agents contained therein, are also provided.
Nº publicación: IL321026A 01/07/2025
Applicant:
RECODE THERAPEUTICS INC [US]
CEFALU JOSEPH S [US]
HENNIG MIRKO [US]
ALFAIFI ALI AHMED [US]
MOHAPATRA SAKYA SING [US]
ISHIMARU DANIELLA [US]
KHARITONOV VLADIMIR GRIGOREVICH [US]
BAEK JULIA JUNG UN [US]
LI SHUANG [US]
LOCKHART DAVID J [US]
WUSTMAN BRANDON A [US]
WANG YUFENG [US]
RECODE THERAPEUTICS INC,
CEFALU Joseph S,
HENNIG Mirko,
ALFAIFI Ali Ahmed,
MOHAPATRA Sakya Sing,
ISHIMARU Daniella,
KHARITONOV Vladimir Grigor'evich,
BAEK Julia Jung-Un,
LI Shuang,
LOCKHART David J,
WUSTMAN Brandon A,
WANG Yufeng
Absstract of: AU2023391361A1
Provided are aerosolized pharmaceutical compositions including aerosol particles, the aerosol particles comprising lipid nanoparticles (LNPs). Also provided herein are liquid pharmaceutical compositions for use in making aerosolized pharmaceutical compositions. Also provided herein are methods of administering the aerosolized pharmaceutical compositions. Also provided herein are kits including a lipid nanoparticle composition including one or more of a phospholipid, an ionizable lipid, a PEG-lipid, a sterol.
BOPI
Electronic site
